MAIL MAN

[righty]

OTCMB NEW FEATURED COMPANY - VIVAKOR INC (VIVK)
Sun, December 13, 2009 7:03:08 PMFrom: "[e-mail]"


--------------------------------------------------------------------------------



VIVAKOR INC


STOCK SYMBOL: VIVK




Vivakor Inc.
2590 Holiday Road
Suite 100
Coralville, IA 52241

http://vivakor.com

Phone: [phone]
Fax: [phone]
E-mail: [e-mail] Vivakor, Inc. is a biotechnology holding company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds, that extend or improve life.


Mission
Vivakor is Inventing Solutions for Life. Vivakor is dedicated to advancing new ideas that improve life for the individual patient, researcher, clinician, and consumer. We don't create science in a vacuum; we push products to market. Our model of innovation spans the continuum from ideas conception to commercialization. We create solutions that positively impact life.


Recent Price Market Capitalization Est. Float Outstanding Shares Quotation
0.255 $13,425,075
as of Dec 11, 2009 50,660,660
as of Jul 15, 2009 OTC:BB


COMPANY OVERVIEW





Vivakor, Inc. (“Vivakor,” the “Company,” or “we”) is a transdisciplinary research company that develops products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds. We also provide contract research services for third parties. We have developed numerous products and have filed many patents or provisional patents with the United States Patent and Trademark Office (USPTO). We intend to commercialize such products, after completion of any required regulatory approvals, through one of three methods: a sale of the technology, licensing of the product to a manufacturer or distributor or, in some cases, by manufacturing, marketing and directly selling the products ourselves.

Our business model is to be a research hub focused on areas that have both an identified scientific need and a substantial market opportunity. Our company mission is to advance new ideas to improve the quality of life for individual patients, researchers, clinician or consumer. We believe that the development of substantive technologies and cures for complex human conditions, illnesses and diseases require a sophisticated approach with contribution from many areas of scientific expertise typically requiring a lengthier trajectory to market. Our hub approach is intended to provide the necessary environment of transdisciplinary collaboration and cross-pollination to advance this type of research. Our research is anchored by our relationship with collaborative partners and product-specific commercialization strategies. From the commencement of product conception through development, we target specific commercialization strategies and expect to have collaborative partners or licensing arrangements in place for each of our products before completion. We expect this model to offer several advantages to our shareholders, including a more efficient research and development process and a quicker time to market after completion of development.

Our pathway for development of products follows one of two routes to commercialization. First is a short-term path in which products for which an expedited regulatory oversight is available are rapidly pushed to the prototype and alpha testing phase. These projects represent rapidly commercializable technologies and products that we expect will have the potential to generate revenue quickly. Second is a long-term path in which more involved and complex projects are developed. These products typically require substantial regulatory oversight or approval. We anticipate that cash flow generated by the short-term projects will help to fund the long-term projects. These longer incubating projects characteristically represent breakthrough technologies with more risk but higher revenue potential.


MARKET SNAPSHOT




PRODUCTS

Vivathermic Vials

VivaThermic CryoVial Technology. We are actively developing the technologies required for the cryopreservation of diverse biological samples with improved recovery of viable cells post-cryopreservation. Emphasis has been placed on strategies to eliminate the variations and time delays experienced in the current biopsy and tissue preservation procedure by integrating a cryogenic freezing capacity into the biopsy device.


Vivaslices

SLICES™. Our acquisition of HealthAmerica’s SLICES™ technology will provide a technology platform for optimization and adaptation by our scientists. This patented technology has received FDA 510(k) clearance and it is intended that this technology will enhance the resolution of images resulting from MRI. The underlying algorithm may be useful in the determination of blood flow velocity measures in imaged tissues. Such information would be valuable in accessing areas of blood flow constriction from plaques or other hematologic deposits. This information could help physicians better diagnose, predict and assess stroke and related diseases involving blood flow obstruction.


Vivasight

VivaSight (Digital PhotoRefractor or DPR). We have developed a device that we expect will modernize screening of pre-verbal and pre-literate children for ocular disorders. This type of screening is increasingly required by state governments prior to enrollment in the public school system. Our scientists are collaborating with physicians and clinicians at University of Iowa Hospitals & Clinics Department of Ophthalmology & Visual Sciences to develop a clinic-ready device.

Data from the National Eye Institute (NEI) states that 2.3 million children have undiagnosed eye disorders that can lead to blindness if left untreated. Amblyopia, commonly known as “lazy eye”, is the leading cause of monocular vision loss in the 20 to 70+ age range. It causes more vision loss than diabetic retinopathy, glaucoma, macular degeneration, and cataracts. Amblyopia occurs when the optical powers of the two eyes are different and the brain favors the visual signal from one eye, functionally ignoring the vision in the amblyopic eye. According to the NEI, an estimated 300,000 to 750,000 children between the ages of three to five suffer from amblyopia. Visual acuity develops principally during the pre-school years, from birth to about five years old, as a child’s visual experience molds its genetic blueprint into its adult visual sensory system. If treatment is not initiated during the visual maturation period, the prognosis for normal visual development is poor. Amblyopia can be reversed and cured if it is detected and treated during the critical visual development period. Unfortunately, less than 21% of preschool children receive some form of vision screening each year. Even those who are screened are often improperly screened by a general health practitioner, pediatrician or screening volunteer due to inadequate experience and lack of equipment or techniques for an assiduous exam. Some children receive proper eye exams once they start school; unfortunately by then it may be too late to effectively treat amblyopia.

Our DPR has been designed with ongoing end-user input to produce a device that will readily penetrate and gain wide acceptance in the vision screening market. Most importantly our DPR offers all screening programs a low cost device with a high sensitivity and specificity. This device will streamline the screening process by the following: 1) Eliminate recurring cost of Polaroid film, 2) Instantaneously image a subject across two meridians of strabismus and refractive error, 3) Detect improper subject fixation, 4) Digitize and automate the interpretation process, 5) Quantify the image interpretation and adjust the referral criteria based upon screening demographics to achieve predetermined levels of sensitivity and specificity, and 6) Give an instant refer/do not refer response to the screener. This device is currently in clinical testing and is in Phase II of the development process. On May 5, 2009, the National Institute of Health through the National Eye Institute awarded us a Phase I Small Business Innovation Research Award grant in the amount of $112,912 to conduct research related to the development of the our DPR and the detection of amblyogenic risk factors.
RECENT COMPANY NEWS




Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products Dec 10 2009, 8:00 AM EST

Vivakor Announces New Acquisition Strategy Dec 9 2009, 4:17 PM EST

Vivakor Announces Mechanics of Dividend Distribution Dec 8 2009, 11:11 AM EST

Vivakor Announces Additions to Board of Directors and Scientific Advisory Board Dec 7 2009, 8:30 AM EST

Vivakor Confirms Record Date of Stock Dividend Dec 4 2009, 2:09 PM EST



--------------------------------------------------------------------------------




Disclaimer Release Of Liability: OTCMarketBulls.com is an independent electronic publication, which provides industry data and information on publicly traded companies for the use of our readers. All material herein is information supplied by the company or other sources believed to be reliable. The information contained herein is not guaranteed by OTCMarketBulls.com to be accurate, and should not be considered to be all-inclusive. This profile contains forward-looking statements that involve risks and uncertainties. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward looking statements. Statements in this press release about the companys future expectation! s other than historical facts, are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, section 21E of the Securities Act of 1934, as that term is defined in the Private Securities Reform Act of 1995. Investors are cautioned that any information in this communication contains certain such forward-looking statements that involve substantial risks and uncertainties. When used, the words "anticipate," "believe," "estimate," "expect," and similar expressions, as they relate to the company or its management, are intended to identify such forward-looking statements. The company's actual results, performance or achievements could differ materially from the results expressed in, or implied by, these forward looking statements. Such "forward-looking statements" are subject to risks and uncertainties set forth from time to time in the companys SEC reports that could cause results to differ materially from those expressed or implied include, but are not limited to, the results of future tests and the availability of funding for additional research and development. This material is for informat ional purposes only and should NOT be construed as an offer or solicitation of an offer to buy or sell any se curit ies. OTCMarketBulls may liqu i date any securities issued when deemed appropriate to do so. Such liquidation may have a negative impact on the securities being liquidated. OTCMarketBulls is not a licensed broker, broker dealer, market marker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on www.otcmarketbulls.com. OTCMarketBulls and/or its affiliates have received fifty thousand dollars from a third party for advertising. OTCMarketBulls affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this profile and may profit in the event those shares rise! in value. OTCMarketBulls does not and will not offer any opinion as to when others should sell; each investor must make that decision.






Please Click here to unsubscribe OTC Newsletter.